Physician profile
Paul Feldman
NPI 1497844757
$6,970.92
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $1,041 · 2021: $1,034 · 2022: $1,325 · 2023: $1,752 · 2024: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693 · Education: $113 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.63 |
| Education | $113.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,188.36 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $826.26 | 2019-2024 | Tavneos, Krystexxa, Parsabiv |
| Vifor Pharma, INC. | $581.78 | 2019-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $400.39 | 2019-2024 | Velphoro, Korsuva |
| Mallinckrodt Hospital Products INC. | $373.58 | 2020-2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $341.73 | 2019-2024 | Jynarque |
| Horizon Therapeutics Plc | $330.74 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $297.56 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $291.80 | 2021-2024 | Jesduvroq, Benlysta |
| Ani Pharmaceuticals, INC. | $259.44 | 2022-2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $243.36 | 2019-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $233.55 | 2020-2024 | Livtencity, Gattex |
| Calliditas Therapeutics US INC. | $222.30 | 2022-2023 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $201.63 | 2021-2024 | |
| Akebia Therapeutics INC | $149.25 | 2019-2024 | Auryxia, Vafseo |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.